China Cancer Biomarkers Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2033

Cancer Biomarkers Market Size

• The China Cancer Biomarkers market size was valued at USD 1.53 billion in 2025 and is expected to reach USD 5.75 billion by 2033, at a CAGR of 18.00% during the forecast period
• The market growth is largely fueled by the increasing adoption of precision medicine, along with continuous technological progress in genomics, proteomics, and molecular diagnostics, leading to greater integration of advanced biomarker-based testing in both clinical and research settings
• Furthermore, rising demand for early cancer detection, personalized treatment planning, and improved patient outcomes is positioning cancer biomarkers as a critical component of modern oncology practices. These converging factors are accelerating the uptake of Cancer Biomarkers solutions, thereby significantly boosting the industry’s growth

Cancer Biomarkers Market Analysis

• Cancer biomarkers, offering critical biological indicators for cancer detection, prognosis, treatment selection, and disease monitoring, are increasingly vital components of modern oncology and precision medicine in both clinical and research settings due to their ability to enable early diagnosis and personalized therapeutic strategies
• The escalating demand for cancer biomarkers is primarily fueled by the increasing global cancer burden, rapid advancements in genomic and proteomic technologies, rising awareness of early screening programs, and a growing preference for targeted and personalized treatments
• China dominated the Cancer Biomarkers market with the largest revenue share of 44.6% in 2025, characterized by substantial government investment in biotechnology, expanding cancer research initiatives, and a strong presence of diagnostic and biopharmaceutical companies, with provinces such as Guangdong, Jiangsu, Zhejiang, Beijing, and Shanghai experiencing significant growth in Cancer Biomarkers development and adoption, particularly in advanced hospitals and research centers, driven by innovations in precision medicine, genomics, and molecular diagnostics
• The genetic biomarkers segment dominated the largest market revenue share of 47.8% in 2025, driven by its extensive application in early cancer detection, targeted therapy selection, treatment response monitoring, and recurrence prediction

Report Scope and Cancer Biomarkers Market Segmentation

Cancer Biomarkers Market Trends

Advancements in Precision Medicine and Multi-Omics Profiling

• A significant and rapidly accelerating trend in the China cancer biomarkers market is the increasing adoption of precision medicine approaches combined with advanced multi-omics profiling techniques, including genomics, proteomics, transcriptomics, and metabolomics. This convergence of scientific disciplines is significantly improving the accuracy of cancer detection, classification, and treatment response monitoring
  • For instance, the growing availability of next-generation sequencing (NGS) platforms in China enables comprehensive genomic profiling of tumors, supporting the identification of actionable mutations and personalized therapy targets. Similarly, the expanding use of liquid biopsy technologies is allowing non-invasive detection of circulating tumor DNA (ctDNA) and other biomarkers in blood samples, offering faster and more convenient diagnostic insights for patients
• The integration of high-throughput analytical platforms in biomarker research has enabled researchers to analyze large volumes of patient data and identify novel biomarker signatures associated with specific cancer subtypes. In addition, advanced bioinformatics tools assist in interpreting complex datasets, facilitating improved risk stratification, predictive modeling, and therapy selection. These advancements collectively contribute to more individualized and effective oncology care pathways
• The increasing collaboration between biotech firms, academic research institutions, and clinical laboratories is strengthening the development and validation of new biomarker panels. This collaborative ecosystem is allowing the translation of laboratory discoveries into clinically actionable diagnostic tests. Through centralized platforms, clinicians can gain insights into tumor behavior, disease progression, and treatment resistance mechanisms, supporting more informed medical decision-making
• This shift toward more integrated, data-driven, and personalized oncology solutions is fundamentally reshaping expectations within the Chinese healthcare ecosystem. As a result, companies and research organizations in China are actively investing in biomarker discovery platforms, companion diagnostics, and molecular testing services to support targeted cancer therapies and immuno-oncology strategies
• The demand for advanced cancer biomarkers is expanding rapidly across hospital laboratories, research centers, pharmaceutical companies, and diagnostic service providers, as healthcare practitioners aim to improve early detection rates, optimize treatment planning, and enhance patient outcomes through precision-based interventions

Cancer Biomarkers Market Dynamics

Driver

Rising Cancer Prevalence and Growing Demand for Early & Accurate Diagnosis

• The increasing prevalence of cancer cases across China, driven by factors such as aging population, environmental exposure, and lifestyle changes, is a significant driver for the growing demand for cancer biomarker testing and research applications
  • For instance, increasing government focus on cancer screening programs and oncology research initiatives has encouraged hospitals and laboratories to adopt advanced biomarker-based diagnostic tools. These supportive policies and rising healthcare investments are expected to strengthen the development and adoption of cancer biomarker technologies throughout the forecast period
• As awareness about early cancer detection improves among both healthcare professionals and the general population, there is a stronger emphasis on identifying diseases at earlier and more treatable stages. Cancer biomarkers play a critical role in enabling earlier diagnosis, monitoring disease progression, and predicting therapeutic responses, offering a clear advantage over conventional diagnostic methods
• Furthermore, the rapid expansion of targeted therapies and immunotherapies has increased the need for specific and reliable biomarkers to identify suitable patient populations. Biomarker testing is increasingly being incorporated into clinical workflows for treatment selection, monitoring drug effectiveness, and evaluating disease recurrence
• The growing presence of biotechnology companies, contract research organizations (CROs), and diagnostic kit manufacturers in China is further contributing to market momentum. These entities are actively involved in biomarker validation, companion diagnostic development, and clinical trial support services
• The continuous improvement in laboratory infrastructure, wider accessibility to advanced testing equipment, and the increasing availability of skilled professionals specializing in molecular diagnostics are collectively accelerating the growth of the China Cancer Biomarkers market

Restraint/Challenge

High Testing Costs, Technical Complexity, and Regulatory Barriers

• Despite strong market potential, the relatively high cost associated with advanced cancer biomarker testing remains a major challenge, particularly in rural or underdeveloped regions. Sophisticated technologies such as next-generation sequencing and multiplex immunoassays often require expensive instruments and specialized reagents, making them less accessible to smaller healthcare facilities
  • For instance, in several tier-2 and tier-3 cities in China, many regional hospitals still lack access to advanced molecular diagnostic equipment such as next-generation sequencing platforms and high-throughput mass spectrometry systems. As a result, patient samples often need to be sent to centralized urban laboratories, leading to longer turnaround times, increased logistic costs, and delayed clinical decision-making, which limits the real-time effectiveness of biomarker-driven cancer treatment strategies
• Regulatory hurdles also pose challenges for market participants. Cancer biomarkers used as companion diagnostics must undergo rigorous evaluation for accuracy, reliability, and clinical relevance before they can receive approval for widespread use. These long and often costly approval processes can delay product launches and slow market entry
• Variability in biomarker expression across different populations and cancer types can also affect the consistency and reproducibility of test results, creating additional challenges for standardization. This highlights the need for extensive clinical trials and population-specific research to ensure reliable outcomes
• While technological innovation continues to improve test accuracy and efficiency, pricing pressures and reimbursement limitations may hinder widespread adoption in cost-sensitive healthcare settings. Many healthcare providers may hesitate to implement high-end biomarker panels unless cost-effectiveness can be clearly demonstrated
• Overcoming these challenges through government support, increased funding for oncology research, workforce training programs, and the development of more cost-effective testing solutions will be essential for sustaining long-term market growth in the China Cancer Biomarkers landscape.

Cancer Biomarkers Market Scope

The market is segmented on the basis of type, biomolecule, technology, cancer type, and application.

• By Type

On the basis of type, the Cancer Biomarkers market is segmented into genetic biomarkers, protein biomarkers, epigenetic biomarkers, glycan biomarkers, and metabolic biomarkers. The genetic biomarkers segment dominated the largest market revenue share of 47.8% in 2025, driven by its extensive application in early cancer detection, targeted therapy selection, treatment response monitoring, and recurrence prediction. Genetic biomarkers play a critical role in identifying mutations such as BRCA1/BRCA2, EGFR, KRAS, and BRAF, which guide oncologists in choosing personalized therapies. The widespread adoption of next-generation sequencing (NGS) and liquid biopsy technologies has significantly strengthened the demand for genetic biomarkers in both clinical and research settings. Additionally, increasing investments in genomic research and expanding companion diagnostic approvals have further supported the dominance of this segment. Research institutes, hospitals, and pharmaceutical companies actively rely on genetic biomarker profiling for precision medicine programs. The availability of advanced sequencing platforms and falling costs of genomic testing have further accelerated large-scale adoption. Furthermore, strong government funding for genomics research in countries such as China and the U.S. has increased the utilization of genetic biomarkers for population-based cancer screening. The integration of artificial intelligence for variant analysis has enhanced the accuracy and reliability of genetic biomarker testing. Biopharmaceutical companies are also increasingly using these biomarkers in clinical trials to improve patient stratification. As a result, the genetic biomarkers segment continues to retain its leadership position within the market.

The epigenetic biomarkers segment is anticipated to witness the fastest growth at a CAGR of 16.4% from 2026 to 2033, driven by growing recognition of the role of DNA methylation, histone modification, and chromatin remodeling in cancer development and progression. Epigenetic changes are reversible, making them attractive targets for novel cancer therapies and early diagnostic tools. Researchers and clinicians are increasingly using epigenetic assays to identify cancer-specific methylation patterns for early-stage detection. These biomarkers are gaining high interest in colorectal, lung, and pancreatic cancer screening programs. The rapid development of epigenetic drugs and ongoing clinical trials targeting epigenetic alterations are accelerating market growth. Improved sensitivity of epigenetic biomarker detection technologies has made them suitable for non-invasive liquid biopsies. Pharmaceutical companies are expanding collaborations with research labs to identify new epigenetic targets. In addition, rising adoption of personalized treatment strategies is encouraging wider use of epigenetic biomarker testing. Growing awareness among oncologists about epigenomics is also contributing to increased test volumes. Technological advancements in sequencing and chromatin analysis tools are improving accessibility. As a result, the epigenetic biomarkers segment is expected to exhibit the highest growth rate during the forecast period.

• By Biomolecule

On the basis of biomolecule, the Cancer Biomarkers market is segmented into DNA, RNA, proteins, and other biomolecules. The DNA segment dominated the market with a revenue share of 45.3% in 2025, due to its central role in identifying genetic mutations, chromosomal alterations, and tumor-specific changes associated with different cancer types. DNA-based biomarkers form the foundation of most modern cancer diagnostic and prognostic tests, including PCR-based assays and NGS-based tests. The increasing use of DNA analysis in minimal residual disease detection and circulating tumor DNA (ctDNA) testing has further strengthened demand. Extensive applications in companion diagnostics and therapy monitoring have made DNA biomarkers indispensable in oncology. The high stability of DNA compared to RNA makes it easier to extract and analyze, enhancing its clinical utility. Growing government initiatives supporting genetic screening programs have expanded its use across hospitals and research laboratories. The presence of well-established protocols for DNA analysis and widespread availability of sequencing platforms have further driven the segment’s dominance. Pharmaceutical companies frequently rely on DNA biomarkers to identify patient populations suitable for clinical trials. The rapid expansion of precision oncology has also increased clinical dependence on DNA molecular profiling. With continued innovation in sequencing technology, DNA-based biomarker analysis is becoming faster, more accurate, and more affordable. These factors collectively ensured its highest revenue contribution in 2025.

The RNA segment is expected to grow at the fastest CAGR of 15.7% from 2026 to 2033, owing to the rising use of transcriptomic profiling to analyze gene expression changes in cancer. RNA biomarkers are critical for understanding tumor behavior, treatment response, and disease progression. The growing interest in microRNAs (miRNA) and messenger RNA (mRNA) signatures for breast, lung, and liver cancers is accelerating market expansion. Advances in RNA sequencing (RNA-seq) technologies have improved accuracy and reduced costs of transcriptomic studies. RNA-based liquid biopsy tests are gaining popularity for non-invasive cancer detection. Increased focus on immuno-oncology and tumor microenvironment analysis has raised the relevance of RNA biomarkers. Biotech companies are increasingly investing in RNA-based test development and therapeutic research. Their application in real-time monitoring of treatment effectiveness is becoming more widespread. Rising research funding in transcriptomics is further supporting this growth. Emerging applications in early-stage cancer detection are expanding the patient base. Resultantly, RNA biomarkers are projected to experience the fastest growth during the forecast period.

• By Technology

On the basis of technology, the Cancer Biomarkers market is segmented into Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunoassays, Microarrays, and Mass Spectrometry. The Next-Generation Sequencing (NGS) segment dominated the market with a share of 42.6% in 2025, due to its ability to analyze multiple genes simultaneously with high sensitivity and accuracy. NGS is widely used in large-scale genomic profiling, which is essential for identifying complex mutations across different cancer types. Its high throughput, decreasing cost per sample, and improved turnaround times have made it the preferred technology in clinical laboratories. The growing adoption of liquid biopsy testing has also fueled NGS usage. Pharmaceutical companies rely heavily on NGS for drug discovery and patient stratification in clinical trials. Hospitals are increasingly establishing in-house NGS laboratories to support precision medicine initiatives. Strong bioinformatics support further enhances the use of NGS data in treatment planning. Government support for genomic research, particularly in China and the U.S., has stimulated installations of advanced NGS platforms. Continuous innovation by leading companies is improving speed and affordability. These combined factors have positioned NGS as the leading technology.

The Mass Spectrometry segment is projected to be the fastest-growing, with a CAGR of 14.9% from 2026 to 2033, driven by its increasing use in proteomics and metabolomics studies for cancer biomarker discovery. Mass spectrometry enables precise detection of protein and metabolic changes associated with cancer development. Its high sensitivity and specificity make it valuable for identifying novel tumor-specific proteins. Technological advancements have reduced sample preparation time and increased analytical capabilities. It is increasingly used in combination with other technologies to improve diagnostic accuracy. Research institutions are expanding the use of mass spectrometry for biomarker validation and high-throughput analysis. Growing interest in personalized treatment is encouraging its adoption in clinical laboratories. Pharmaceutical companies are utilizing this technology in drug development and response monitoring. Rising investment in proteomics and metabolomics research is further accelerating growth. As awareness of its clinical value increases, adoption is expected to expand rapidly. Consequently, mass spectrometry is forecast to register the highest growth rate during the forecast period.

• By Cancer Type

On the basis of cancer type, the Cancer Biomarkers market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, and other cancer types. The breast cancer segment dominated the market with a share of 38.4% in 2025, due to the high global prevalence of breast cancer and strong screening initiatives. Widespread use of HER2, BRCA, and hormone receptor biomarkers in diagnosis and treatment contributes significantly to market demand. Extensive awareness programs and government-supported screening campaigns have increased testing volume. The high rate of R&D investments in breast cancer has led to the discovery of multiple predictive and prognostic biomarkers. Development of targeted therapies such as HER2 inhibitors depends heavily on biomarker testing. The availability of advanced diagnostic infrastructure has further strengthened this segment. Continuous innovation in early detection methods has encouraged widespread adoption. Increased survival awareness has pushed demand for monitoring biomarkers. Pharmaceutical companies are actively developing new companion diagnostics for breast cancer therapies. These factors combined have ensured the segment’s leadership position.

The lung cancer segment is expected to grow at the fastest CAGR of 15.2% from 2026 to 2033, due to rising incidence, especially in urban and industrial regions. Biomarkers such as EGFR, ALK, and PD-L1 are increasingly used to guide targeted and immunotherapy treatments. Growing adoption of non-invasive liquid biopsy tests for lung cancer detection is also driving growth. Improved access to molecular testing in emerging countries is expanding the patient base. Government initiatives for early detection of lung cancer are contributing to higher testing rates. Pharmaceutical advancements in immuno-oncology rely heavily on lung cancer biomarkers. Technological advancements in testing platforms are improving accuracy. Continuous innovation in targeted therapies is boosting demand. Increased smoking-related health awareness is encouraging early testing. As a result, lung cancer biomarkers are projected to witness rapid expansion over the forecast period.

• By Application

On the basis of application, the Cancer Biomarkers market is segmented into drug discovery & development, diagnosis, prognosis, and personalized medicine. The diagnosis segment accounted for the largest market revenue share of 41.9% in 2025, driven by the rising demand for early cancer detection and accurate disease identification. Biomarkers are extensively used in screening programs to identify cancer at its earliest stage. Hospitals and diagnostic centers have rapidly expanded their biomarker testing infrastructure. Improved patient outcomes from early diagnosis have increased reliance on biomarker-based assays. Growing awareness about preventive healthcare is boosting routine testing volume. The increasing availability of affordable diagnostic kits has also played a major role. Government support for national cancer screening programs continues to drive demand. Biomarkers have become standard components of oncology diagnostic protocols. Increased integration of AI in diagnostics is improving test accuracy. These improvements have strengthened the dominance of the diagnosis segment.

The personalized medicine segment is expected to experience the fastest growth, with a CAGR of 16.8% from 2026 to 2033, driven by the shift toward individualized treatment strategies based on patient-specific biomarker profiles. Rising use of companion diagnostics has fueled this growth. Oncologists increasingly rely on biomarkers to select the most effective therapy for each patient. Growth in genomic and molecular data analysis is strengthening the foundation for precision treatment. Pharmaceutical companies are focusing on targeted drugs that require biomarker confirmation. Growing investments in precision oncology are supporting this expansion. Advancements in data analytics and AI tools are improving treatment customization. Increased success rates of targeted therapies are boosting confidence in personalized approaches. The rising number of biomarker-based clinical trials is also accelerating development. Hence, personalized medicine is projected to be the fastest-growing application segment.

Cancer Biomarkers Market Share

The Cancer Biomarkers industry is primarily led by well-established companies, including:

• Illumina (U.S.)
• Bio-Rad Laboratories (U.S.)
• BGI Genomics (China)
• Burning Rock Dx (China)
• Berry Genomics (China)
• Novogene (China)
• Guardant Health (U.S.)
• Foundation Medicine (U.S.)
• Myriad Genetics (U.S.)
• PerkinElmer (U.S.)
• Abbott (U.S.)
• Danaher Corporation (U.S.)
• GenScript Biotech (China)
• AmoyDx (China)
• Sysmex Corporation (Japan)
• Natera (U.S.)

Latest Developments in China Cancer Biomarkers Market

• In October 2023, Geneseeq Technology received NMPA approval for its NSCLC Tumor Mutational Burden (TMB) Test Kit. This NGS-based kit, covering a 425-gene panel, is intended to help predict the efficacy of immune checkpoint inhibitor therapy in Chinese lung cancer patients
• In October 2024, Burning Rock Biotech and Dizal announced that China’s NMPA granted marketing approval for their co-developed NGS-based companion diagnostic (CDx) test, LungCure CDx, which targets the EGFR exon 20 insertion mutation in non–small-cell lung cancer
• In April 2025, Promega announced that its ProDx MSI Detection Kit secured an “Innovative Medical Device” registration certificate from China’s NMPA. The kit detects microsatellite instability (MSI) in colorectal tumor tissues — a key biomarker for Lynch syndrome and immunotherapy responsiveness

SKU-72800